Amylx Pharmaceuticals Inc vs Dow Jones Industrial Average ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Dow Jones Industrial Average ETF trades at $537.97. Which is the better fit depends on your goals.
| AMLX | DIA | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | — |
52-Week High | $24.19 | $542.79 |
52-Week Low | $7.82 | $444.64 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →